Researchers participating in ORIEN's Avatar program can use the platform to manage, share, integrate, and analyze molecular data from consenting patients.
The WGS service will be provided by Genome.One, a new health information company owned by and based at the Garvan Institute of Medical Research in Sydney.
The combined solution gives customers access to the bioinformatics tools and genomic intelligence to help them analyze data and make business decisions.
In a JNCCN paper, the investigators discussed their efforts to comprehensively characterize a single patient's breast tumor and test potential treatments.
The FDA established the platform to allow scientists to test their NGS assays and to advance the regulatory science for assessing genomic tests and software.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
